Treatment for Infantile Hemangiomas
| Autor: | Deepak Mehta, Susan Geisler, Lorelei J. Grunwaldt, Robin Gehris, Zoe M. MacIsaac, Harry S. Nayar |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty Esthetics Visual Analog Scale Visual analogue scale Adrenergic beta-Antagonists Administration Oral Antineoplastic Agents Propranolol Cohort Studies Hemangioma 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine 030225 pediatrics Infantile hemangioma medicine Humans Retrospective Studies Retrospective review business.industry Patient Selection Body Weight Infant Newborn Infant Retrospective cohort study General Medicine medicine.disease Surgery body regions Treatment Outcome Otorhinolaryngology Head and Neck Neoplasms Female Lost to Follow-Up Safety Early phase business Follow-Up Studies Cohort study medicine.drug |
| Zdroj: | Journal of Craniofacial Surgery. 27:159-162 |
| ISSN: | 1049-2275 |
| DOI: | 10.1097/scs.0000000000002206 |
| Popis: | Despite the increasing popularity of propranolol for treatment of infantile hemangioma (IH), there is need for further evidence of efficacy and safety. This study is a retrospective review of one institution's experience treating IH with propranolol using a standard protocol.Between 2009 and 2014, patients with IH were evaluated for treatment with propranolol. Exclusion criteria included a history of hypoglycemia, respiratory disorders, and cardiovascular disorders. Propranolol, 2 mg/kg/d, was initiated during 48-hour inpatient stay. Weight and complications were monitored. Appearance was assessed by Visual Analog Cosmetic Scale (VACS) via serial photography.Twenty-three patients were treated with propranolol. Average age at initiation of therapy was 14.9 weeks. Twenty-two lesions were on the head and neck, and 1 was on the trunk. Average treatment duration was 54.3 weeks (range 24-148 wk). Treatment was confirmed to be complete in 23 patients at the time of review (91.3%). Two patients were lost to follow-up. Posttreatment color, size, and VACS improved significantly (P0.05). There was no significant difference between first and most recent weight. Two patients experienced hypoglycemia, 1 during a diarrheal illness and 1 during inpatient treatment initiation.The authors present a series of patients with IH safely treated with 2 mg/kg/d of propranolol. Using a strict protocol, few complications were observed. Patients achieved significant reduction in size and improvement of the overall appearance of IH. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|